AMRX — Amneal Pharmaceuticals Balance Sheet
0.000.00%
- $2.34bn
- $4.84bn
- $2.79bn
- 66
- 86
- 68
- 86
Annual balance sheet for Amneal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 341 | 248 | 26 | 91.5 | 111 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 674 | 728 | 797 | 646 | 809 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,552 | 1,520 | 1,412 | 1,378 | 1,588 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 605 | 639 | 589 | 550 | 524 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 4,006 | 3,940 | 3,799 | 3,473 | 3,501 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 677 | 677 | 753 | 847 | 1,130 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 3,703 | 3,579 | 3,501 | 3,453 | 3,611 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 303 | 360 | 298 | 19.8 | -109 |
Total Liabilities & Shareholders' Equity | 4,006 | 3,940 | 3,799 | 3,473 | 3,501 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |